Literature DB >> 28257791

Safety and efficacy of cap-assisted EMR for sporadic nonampullary duodenal adenomas.

Laith H Jamil1, Amir Kashani1, Neiveen Peter2, Simon K Lo1.   

Abstract

BACKGROUND AND AIMS: Eradication of sporadic nonampullary duodenal adenomas (SNADAs) is essential because of their high rate of malignant transformation. EMR techniques are the alternative to the traditional surgical treatments of SNADAs. There are very limited data on the safety and efficacy of cap-assisted EMR (C-EMR) in the treatment of SNADA.
METHODS: The medical records of patients who underwent C-EMR for SNADAs between July 2002 and April 2013 were retrospectively reviewed. Eradication was defined as no residual adenoma on follow-up or en bloc resection on pathology. Recurrence was defined as finding adenoma after a negative follow-up.
RESULTS: Fifty-nine C-EMR sessions were performed on 49 SNADAs (flat, 46; sessile, 3); 39 polyps were treated in piecemeal fashion and 10 polyps with en bloc resection. The polyp histology was tubular adenoma (63.3%) and tubulovillous adenoma (36.7%), with 16.3% of lesions showing high-grade dysplasia. Initial eradication rate was 90.5%; residual adenomas were successfully treated with repeat C-EMR/snare, resulting in 100% ultimate eradication rate without any recurrences (median follow-up of 17 months). The overall adverse events rate was 16.9%: intraprocedural bleeding (10.2%), delayed GI bleeding (5.1%), and perforation (1.7%). Among large polyps (≥15 mm), the initial and ultimate eradication rates were 87.9% and 100%, respectively, and the adverse event rate was 17%. Initial eradication rate for small polyps was higher than in large polyps (100% vs 87.9%, respectively; P = .02).
CONCLUSION: C-EMR is a highly efficient and safe method for the treatment of SNADAs. We recommend that endoscopists should learn C-EMR on esophageal, gastric, rectal, or left-sided colonic lesions before attempting C-EMR in the duodenum.
Copyright © 2017 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28257791     DOI: 10.1016/j.gie.2017.02.023

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  4 in total

1.  Comparisons of therapeutic outcomes in patients with nonampullary duodenal neuroendocrine tumors (NADNETs): A multicenter retrospective study.

Authors:  Seung Woo Lee; Jae Kyu Sung; Young Sin Cho; Ki Bae Bang; Sun Hyung Kang; Ki Bae Kim; Sae Hee Kim; Hee Seok Moon; Kyung Ho Song; Sun Moon Kim; Il-Kwun Chung; Dong Soo Lee; Hyun Yong Jeong; Sei Jin Youn
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

2.  Outcomes of endoscopic mucosal resection for large superficial non-ampullary duodenal adenomas.

Authors:  Maxime Amoyel; Arthur Belle; Marion Dhooge; Einas Abou Ali; Anna Pellat; Rachel Hallit; Benoit Terris; Frédéric Prat; Stanislas Chaussade; Romain Coriat; Maximilien Barret
Journal:  Sci Rep       Date:  2022-08-26       Impact factor: 4.996

3.  The Efficacy of Autologous Myoblast Sheet Transplantation to Prevent Perforation After Duodenal Endoscopic Submucosal Dissection in Porcine Model.

Authors:  Ryo Matsumoto; Kengo Kanetaka; Yasuhiro Maruya; Shun Yamaguchi; Shinichiro Kobayashi; Daisuke Miyamoto; Ken Ohnita; Yusuke Sakai; Keiichi Hashiguchi; Kazuhiko Nakao; Susumu Eguchi
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 4.  Endoscopic management of non-ampullary duodenal adenomas.

Authors:  Maxime Amoyel; Arthur Belle; Marion Dhooge; Einas Abou Ali; Rachel Hallit; Frederic Prat; Anthony Dohan; Benoit Terris; Stanislas Chaussade; Romain Coriat; Maximilien Barret
Journal:  Endosc Int Open       Date:  2022-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.